Physician profile
Bianca Ramirez
NPI 1609215649
$1,288.31
in general payments reported to CMS, 2019-2025
18 companies · $817 in 2025
The $817 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $58.81 · 2023: $182 · 2024: $231 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $238.58 | 2023-2025 | Gocovri, Qelbree, Gocovri |
| Neurocrine Biosciences, INC. | $160.79 | 2023-2025 | Ingrezza |
| Globus Medical, INC. | $147.85 | 2025 | Senza |
| Lilly USA, LLC | $125.00 | 2025 | Kisunla |
| Urogen Pharma, INC. | $113.64 | 2025 | |
| Acadia Pharmaceuticals INC | $82.92 | 2023-2024 | Nuplazid |
| Abbvie INC. | $61.03 | 2023-2025 | |
| Boston Scientific Corporation | $58.81 | 2022 | |
| Eisai INC. | $56.39 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $52.96 | 2025 | Rexulti |
| Ucb, INC. | $41.88 | 2024 | Rystiggo, Zilbrysq |
| Alnylam Pharmaceuticals INC. | $34.35 | 2025 | Oxlumo |
| Corium, LLC | $24.08 | 2023 | Adlarity |
| Vertex Pharmaceuticals Incorporated | $22.76 | 2025 | |
| Neurelis, INC. | $19.51 | 2025 | Valtoco |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.33 | 2023 | |
| Janssen Biotech, INC. | $16.41 | 2025 | Erleada |
| Nalu Medical, INC. | $14.02 | 2025 | Nalu Neurostimulation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bianca Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.